# Role of Microglial Activation and Norepinephrine Transporter Abnormalities in Pathogenesis of MS-related Fatigue

> **NCT04144257** · PHASE1,PHASE2 · COMPLETED · sponsor: **Brigham and Women's Hospital** · enrollment: 10 (actual)

## Conditions studied

- Multiple Sclerosis

## Interventions

- **DRUG:** [F-18]PBR06
- **DRUG:** [C-11]Methylreboxetine

## Key facts

- **NCT ID:** NCT04144257
- **Lead sponsor:** Brigham and Women's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-03-12
- **Primary completion:** 2021-04-13
- **Final completion:** 2021-04-13
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2026-05-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04144257

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04144257, "Role of Microglial Activation and Norepinephrine Transporter Abnormalities in Pathogenesis of MS-related Fatigue". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT04144257. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*